Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
05 Apr 2017 EMA Publishes Framework and Action Plan for Closer Interaction with the Academic Community Bioethics, legal and economic issues
04 Apr 2017 NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
03 Apr 2017 FDA Grants Regular Approval to Palbociclib as Initial Endocrine Based Therapy Breast cancer - Anticancer agents & Biologic therapy
31 Mar 2017 FDA Grants Regular Approval to Osimertinib Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
30 Mar 2017 EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Dinutuximab beta Apeiron Central nervous system malignancies - Anticancer agents & Biologic therapy
29 Mar 2017 FDA Approves PARP Inhibitor Niraparib Gynaecologic malignancies - Anticancer agents & Biologic therapy
28 Mar 2017 EMA Adopts a New Indication for Pembrolizumab Haematologic malignancies - Cancer Immunology and Immunotherapy
26 Mar 2017 EMA Adopts a New Indication for Nivolumab Head and neck cancers - Cancer Immunology and Immunotherapy
24 Mar 2017 FDA Grants Accelerated Approval to Avelumab Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
16 Mar 2017 FDA Grants Accelerated Approval to Pembrolizumab for the Treatment of Classical Hodgkin Lymphoma Cancer Immunology and Immunotherapy
15 Mar 2017 FDA Approves Ribociclib as Initial Treatment for Postmenopausal Women with HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
14 Mar 2017 EMA Reviewing Cancer Medicine Docetaxel Anticancer agents & Biologic therapy
13 Mar 2017 EMA’s PRAC Concludes Assessment of Gadolinium Agents and Recommends Regulatory Actions, Including Suspension of Some Marketing Authorisations Diagnosis, Imaging and Staging
10 Mar 2017 Use of imatinib in CML has pointed oncology in a new direction Haematologic malignancies - Anticancer agents & Biologic therapy
08 Mar 2017 Clarification of Hepatitis B Virus Status Needed Before Starting Treatment with Pomalidomide Anticancer agents & Biologic therapy